[A new era for glucagon-like peptide-1 receptor agonists].

Jan 12, 2023Revue medicale de Liege

New developments in drugs that activate the GLP-1 receptor

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗

Abstract

Liraglutide at 3.0 mg daily and semaglutide at 2.4 mg weekly are indicated for obesity treatment.

GLP-1 receptor agonists improve glucose control without causing low blood sugar and promote weight loss.
Higher doses of liraglutide, semaglutide, and dulaglutide may result in better glycaemic outcomes and increased weight reduction.
Tirzepatide has demonstrated significant reductions in glycated hemoglobin levels and body weight compared to dulaglutide or semaglutide.
Tirzepatide is approved for treating type 2 diabetes and is being investigated for obesity in the SURMOUNT programme.
New triagonists targeting GIP, GLP-1, and glucagon are under development for managing type 2 diabetes and obesity.

AI simplified

Glucagon-like peptide-1 (GLP-1) receptor agonists have a privileged place in the management of type 2 diabetes (T2D). They not only improve glucose control without inducing hypoglycaemia and trigger weight loss, but also protect against atherosclerotic cardiovascular disease. Increasing the dose of three of them (liraglutide, semaglutide, dulaglutide) allows better glycaemic results and of potential interest a greater weight reduction. Liraglutide at a daily dose of 3.0 mg and semaglutide at a weekly dose of 2.4 mg received the indication for the therapy of obesity. A recent innovation consists in the development of dual unimolecular agonists that target GLP-1 and GIP («glucose-dependent insulinotropic polypeptide») receptors (tirzepatide) or GLP-1 and glucagon receptors (cotadutide). Tirzepatide, in the SURPASS programme, showed impressive reductions in glycated haemoglobin level and body weight, greater than those observed with dulaglutide or semaglutide. Tirzepatide received the indication of the treatment of T2D and is currently tested in obesity (SURMOUNT programme). Interestingly, triagonists GIP/GLP-1/glucagon are currently developed for the management of T2D and obesity, with also perspectives for treating metabolic-associated fatty liver disease.

[A new era for glucagon-like peptide-1 receptor agonists].

Abstract

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief